Novel Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A..

United statesSouth koreaSoult ukpyolsiHeparann sulfataseSohee kimPharma sanfilippoRachel kimYelin junGc biopharma corpGreen cross corporationNovel pharma incNovel pharmaSanfilippo syndrome typeOrphan drug designationRare pediatric disease designationSyndrome type